Remove Engineering Remove Licensing Remove Molecular Biology
article thumbnail

Gamma delta T cells: a rising star in cancer therapy

Drug Target Review

These include engineering the cells to express cytokines that promote their maturation and/or differentiation, and engineering drug-resistant γδ T cells that can be combined with chemotherapies, which stress cancer cells but would otherwise also deplete the T-cell population. and MBA students with real-world consulting experiences.

Therapies 105
article thumbnail

Kiromic Announces the Filing of Key European Patents for Its Chimeric PD-1 (chPD1) Target

The Pharma Data

We believe our allogenic CAR-T platform is significantly stronger with chPD1 target licensed from Longwood University. The pipeline development is leveraged through the Company’s proprietary target discovery engine called “DIAMOND.” Amorette Barber of Longwood University will be heading up our chPD1 program.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Scaling Phage Therapy

Codon

Phage-based products have been licensed for use as antibacterial agents in the sanitation , food production , and animal health industries. Crucially, it could also make them easier to license as therapeutic agents. The resulting data are fed into an analytical engine that runs millions of simulations. aeruginosa, S. pneumoniae.

Therapies 137
article thumbnail

Codon Digest: Seeing Colors After Gene Therapy

Codon

.” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics. You can read all of them here. I’ve written about this before. No longer.

article thumbnail

Codon Digest: Seeing Colors After Gene Therapy

Codon

.” Wellcome Collection , London I wrapped up my series on “30 Days of Great Biology Papers.” ” This was a series of tweets in which I told brief stories behind seminal papers, mostly in molecular biology and biophysics. You can read all of them here. I’ve written about this before. No longer.

article thumbnail

Experts explore the future of iPSC-based cell therapies

Drug Target Review

Dr Frederic Cedrone is the Vice President of Corporate Innovation at Catalent, where he works closely with the Cell and Gene Therapy teams to drive innovation in emerging therapeutic modalities through strategic partnerships, licensing and technology acquisitions.

article thumbnail

The Codon Guide to Synthetic Biology

Codon

Credit: Bruce Wetzel and Harry Schaefer, NCI, NIH | License Progress in biology is arguably moving faster today than at any point in the course of human history. Engineered biology has profound potential to change how we live, but the field has become broad, bloated, nebulous. Journal of Molecular Biology (1961).

DNA 98